Health TrialsbyHealthPanel

Time Restricted Feeding, Muscle, and Metabolism

ConditionsOverweightObesity
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-50
SponsorUniversity of Arkansas, Fayetteville

About this trial

Effective nutrition strategies for combatting and/or preventing obesity still need to be identified. This has been the case despite the numerous and different approaches that have been taken. Potential targets for combatting/preventing obesity have been identified, but long-term solutions have not emerged. This study uses time restricted feeding to study the role of dietary protein in obesity prevention and/or treatment. The objectives are to determine the role of skeletal muscle mass as a driver of energy-sensing mechanisms and peripheral signals that regulate appetite and energy intake in overweight and obese adults and to determine the effects of protein timing on muscle mass to regulate appetite and energy intake in overweight and obese adults.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Resides in Northwest Arkansas

Age 25-50 years

BMI > 25

All ethnicities

Disqualifiers

Food allergies

Pregnant or breastfeeding

Dietary restrictions (e.g. vegetarian, vegan, etc.)

Trying to lose weight in last 3 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • Whey protein supplement

    Dietary supplement

    Participants consume whey protein at the beginning of the eating period.

  • Ketogenic aid

    Dietary supplement

    Participants consume ketogenic aid upon waking.

  • Control group - time restricted feeding only

    Other intervention

    Time restricted feeding.

Treatment groups

90 Participants
are divided into 3 treatment groups
Group A: TRF-CPlacebo comparator 1 intervention
Group B: TRF-PExperimental treatment 1 intervention
Group C: TRF-SExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Body composition

Body composition measured using dual x-ray absorptiometry to determine the ration of lean/fat-free mass to fat mass.

Time frame
Change is being assessed at baseline and final day (day 120) of the intervention.

Secondary outcomes

1

Whole body protein turnover

Whole body protein turnover will be measured using 15N-alanine

Time frame
Change is being assessed at baseline and final day (day 120) of the intervention.
2

Muscle mass

Muscle mass will be measured using D3-creatine

Time frame
Change is being assessed at baseline and final day (day 120) of the intervention.
3

Body weight

Body weight will be measured in kilograms.

Time frame
Change is being assessed at baseline, 4, 8, and 12 weeks.
4

Sleep

Sleep will be assessed using wrist Actigraphy for sleep duration and total time in bed.

Time frame
Change is being assessed at baseline and 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Arkansas, Fayetteville

Lead sponsor

Source ClinicalTrials.gov
Apply now